Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

3T: a Phase II Single Arm Open Label Study of Tucatinib Combined with Trastuzumab and TAS-102 in Molecularly Selected Patients with HER2+ Metastatic Colorectal Cancer

NCT05356897 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.

NCT NCT05356897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05356897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
3T: a Phase II Single Arm Open Label Study of Tucatinib Combined with Trastuzumab and TAS-102 in Molecularly Selected Patients with HER2+ Metastatic Colorectal Cancer
Lead sponsor
Academic and Community Cancer Research United
Phase
Phase 2
Overall status
Withdrawn
Start date
October 31, 2023
Completion date
September 17, 2024
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colon adenocarcinoma, metastatic colorectal adenocarcinoma, metastatic rectal adenocarcinoma, stage iv colon cancer ajcc v8, stage iv colorectal cancer ajcc v8, stage iv rectal cancer ajcc v8